Claus-Michael Lehr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5202908/publications.pdf

Version: 2024-02-01

403 papers 24,692 citations

5782 84 h-index 12638 137 g-index

421 all docs

421 docs citations

times ranked

421

26886 citing authors

#	Article	IF	CITATIONS
1	An Outer Membrane Vesicleâ€Based Permeation Assay (OMPA) for Assessing Bacterial Bioavailability. Advanced Healthcare Materials, 2022, 11, e2101180.	3.9	3
2	Yields and Immunomodulatory Effects of Pneumococcal Membrane Vesicles Differ with the Bacterial Growth Phase. Advanced Healthcare Materials, 2022, 11, e2101151.	3.9	12
3	Exploring the permeation of fluoroquinolone metalloantibiotics across outer membrane porins by combining molecular dynamics simulations and a porin-mimetic in vitro model. Biochimica Et Biophysica Acta - Biomembranes, 2022, 1864, 183838.	1.4	2
4	Targeting extracellular lectins of <i>Pseudomonas aeruginosa</i> with glycomimetic liposomes. Journal of Materials Chemistry B, 2022, 10, 537-548.	2.9	5
5	Nanoâ€inâ€Microparticles for Aerosol Delivery of Antibioticâ€Loaded, Fucoseâ€Derivatized, and Macrophageâ€Targeted Liposomes to Combat Mycobacterial Infections: In Vitro Deposition, Pulmonary Barrier Interactions, and Targeted Delivery. Advanced Healthcare Materials, 2022, 11, e2102117.	3.9	11
6	Models using native tracheobronchial mucus in the context of pulmonary drug delivery research: Composition, structure and barrier properties. Advanced Drug Delivery Reviews, 2022, 183, 114141.	6.6	17
7	Leaky gut model of the human intestinal mucosa for testing siRNA-based nanomedicine targeting JAK1. Journal of Controlled Release, 2022, 345, 646-660.	4.8	10
8	Transferring Microclusters of <i>P. aeruginosa</i> Biofilms to the Air–Liquid Interface of Bronchial Epithelial Cells for Repeated Deposition of Aerosolized Tobramycin. ACS Infectious Diseases, 2022, 8, 137-149.	1.8	8
9	In vitro tools for orally inhaled drug products—state of the art for their application in pharmaceutical research and industry and regulatory challenges. In Vitro Models, 2022, 1, 29-40.	1.0	O
10	Gentamicin nanogel films based on Carrageenan-Prosopis africana for improved wound healing. Precision Nanomedicine, 2022, 5, .	0.4	1
11	Spray-dried pneumococcal membrane vesicles are promising candidates for pulmonary immunization. International Journal of Pharmaceutics, 2022, 621, 121794.	2.6	6
12	Decoding (patho-)physiology of the lung by advanced in vitro models for developing novel anti-infectives therapies. Drug Discovery Today, 2021, 26, 148-163.	3.2	6
13	Development and evaluation of a quality control system based on transdermal electrical resistance for skin barrier function in vitro. Skin Research and Technology, 2021, 27, 668-675.	0.8	1
14	Second-generation lung-on-a-chip with an array of stretchable alveoli made with a biological membrane. Communications Biology, 2021, 4, 168.	2.0	161
15	Microbiota and cancer: In vitro and in vivo models to evaluate nanomedicines. Advanced Drug Delivery Reviews, 2021, 170, 44-70.	6.6	10
16	Formulation and evaluation of transdermal nanogel for delivery of artemether. Drug Delivery and Translational Research, 2021, 11, 1655-1674.	3.0	21
17	A pulmonary mucus surrogate for investigating antibiotic permeation and activity against <i>Pseudomonas aeruginosa</i> biofilms. Journal of Antimicrobial Chemotherapy, 2021, 76, 1472-1479.	1.3	7
18	A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate <i>Pseudomonas aeruginosa</i> Biofilms. Advanced Science, 2021, 8, e2004369.	5.6	34

#	Article	IF	Citations
19	A Custom-Made Device for Reproducibly Depositing Pre-metered Doses of Nebulized Drugs on Pulmonary Cells in vitro. Frontiers in Bioengineering and Biotechnology, 2021, 9, 643491.	2.0	11
20	Mastering the Gram-negative bacterial barrier $\hat{a}\in$ "Chemical approaches to increase bacterial bioavailability of antibiotics. Advanced Drug Delivery Reviews, 2021, 172, 339-360.	6.6	42
21	Testing of aerosolized ciprofloxacin nanocarriers on cystic fibrosis airway cells infected with P. aeruginosa biofilms. Drug Delivery and Translational Research, 2021, 11, 1752-1765.	3.0	15
22	Tobramycin Liquid Crystal Nanoparticles Eradicate Cystic Fibrosisâ€Related <i>Pseudomonas aeruginosa</i> Biofilms. Small, 2021, 17, e2100531.	5.2	37
23	Surfactant-Free Glibenclamide Nanoparticles: Formulation, Characterization and Evaluation of Interactions with Biological Barriers. Pharmaceutical Research, 2021, 38, 1081-1092.	1.7	7
24	Towards More Predictive, Physiological and Animal-free <i>In Vitro</i> Models: Advances in Cell and Tissue Culture 2020 Conference Proceedings. ATLA Alternatives To Laboratory Animals, 2021, 49, 93-110.	0.7	6
25	Extracellular vesicles as novel assay tools to study cellular interactions of anti-infective compounds – A perspective. Advanced Drug Delivery Reviews, 2021, 173, 492-503.	6.6	6
26	Spray-dried lactose-leucine microparticles for pulmonary delivery of antimycobacterial nanopharmaceuticals. Drug Delivery and Translational Research, 2021, 11, 1766-1778.	3.0	16
27	Extracellular vesicles as antigen carriers for novel vaccination avenues. Advanced Drug Delivery Reviews, 2021, 173, 164-180.	6.6	49
28	Drug delivery for fighting infectious diseases: a global perspective. Drug Delivery and Translational Research, 2021, 11, 1316-1322.	3.0	6
29	Towards the sustainable discovery and development of new antibiotics. Nature Reviews Chemistry, 2021, 5, 726-749.	13.8	439
30	Drug delivery to the inflamed intestinal mucosa – targeting technologies and human cell culture models for better therapies of IBD. Advanced Drug Delivery Reviews, 2021, 175, 113828.	6.6	29
31	Pulmonary in vitro instruments for the replacement of animal experiments. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 168, 62-75.	2.0	5
32	PerfuPulâ€"A Versatile Perfusable Platform to Assess Permeability and Barrier Function of Air Exposed Pulmonary Epithelia. Frontiers in Bioengineering and Biotechnology, 2021, 9, 743236.	2.0	9
33	Human Skin Permeation Enhancement Using PLGA Nanoparticles Is Mediated by Local pH Changes. Pharmaceutics, 2021, 13, 1608.	2.0	9
34	Analysis and Optimization of Two Film-Coated Tablet Production Processes by Computer Simulation: A Case Study. Processes, 2021, 9, 67.	1.3	2
35	Systematic Analysis of Composition, Interfacial Performance and Effects of Pulmonary Surfactant Preparations on Cellular Uptake and Cytotoxicity of Aerosolized Nanomaterials. Small Science, 2021, 1, 2100067.	5.8	6
36	Co-Delivery of mRNA and pDNA Using Thermally Stabilized Coacervate-Based Core-Shell Nanosystems. Pharmaceutics, 2021, 13, 1924.	2.0	11

#	Article	IF	CITATIONS
37	Nanoparticle Targeting to Scalp Hair Follicles: NewÂPerspectives for a Topical Therapy for Alopecia Areata. Journal of Investigative Dermatology, 2020, 140, 243-246.e5.	0.3	7
38	PLGA nanocapsules improve the delivery of clarithromycin to kill intracellular Staphylococcus aureus and Mycobacterium abscessus. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102125.	1.7	26
39	Micro-rheological properties of lung homogenates correlate with infection severity in a mouse model of Pseudomonas aeruginosa lung infection. Scientific Reports, 2020, 10, 16502.	1.6	17
40	Towards a Continuous Manufacturing Process of Protein-Loaded Polymeric Nanoparticle Powders. AAPS PharmSciTech, 2020, 21, 269.	1.5	5
41	Coupling quaternary ammonium surfactants to the surface of liposomes improves both antibacterial efficacy and host cell biocompatibility. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 149, 12-20.	2.0	19
42	Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases. Pharmaceutics, 2020, 12, 1131.	2.0	13
43	Itaconic Acid Increases the Efficacy of Tobramycin against Pseudomonas aeruginosa Biofilms. Pharmaceutics, 2020, 12, 691.	2.0	6
44	Synthesis and Biopharmaceutical Characterization of Amphiphilic Squalenyl Derivative Based Versatile Drug Delivery Platform. Frontiers in Chemistry, 2020, 8, 584242.	1.8	6
45	Spray-dried multidrug particles for pulmonary co-delivery of antibiotics with N-acetylcysteine and curcumin-loaded PLGA-nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 157, 200-210.	2.0	27
46	Disease Models: Lung Models for Testing Drugs Against Inflammation and Infection. Handbook of Experimental Pharmacology, 2020, 265, 157-186.	0.9	5
47	Tobacco Smoke and Inhaled Drugs Alter Expression and Activity of Multidrug Resistance-Associated Protein-1 (MRP1) in Human Distal Lung Epithelial Cells in vitro. Frontiers in Bioengineering and Biotechnology, 2020, 8, 1030.	2.0	12
48	A hydrogel-based in vitro assay for the fast prediction of antibiotic accumulation in Gram-negative bacteria. Materials Today Bio, 2020, 8, 100084.	2.6	10
49	Squalenyl Hydrogen Sulfate Nanoparticles for Simultaneous Delivery of Tobramycin and an Alkylquinolone Quorum Sensing Inhibitor Enable the Eradication of <i>P.â€aeruginosa</i> Biofilm Infections. Angewandte Chemie - International Edition, 2020, 59, 10292-10296.	7.2	41
50	Streptococcal Extracellular Membrane Vesicles Are Rapidly Internalized by Immune Cells and Alter Their Cytokine Release. Frontiers in Immunology, 2020, 11, 80.	2.2	64
51	Advancing human <i>in vitro</i> pulmonary disease models in preclinical research: opportunities for <i>lung-on-chips</i> . Expert Opinion on Drug Delivery, 2020, 17, 621-625.	2.4	19
52	Squalenyl Hydrogen Sulfate Nanoparticles for Simultaneous Delivery of Tobramycin and an Alkylquinolone Quorum Sensing Inhibitor Enable the Eradication of P. aeruginosa Biofilm Infections. Angewandte Chemie, 2020, 132, 10378-10382.	1.6	1
53	P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives. Journal of Visualized Experiments, 2020, , .	0.2	18
54	pH-Dependent morphology and optical properties of lysine-derived molecular biodynamers. Materials Chemistry Frontiers, 2020, 4, 905-909.	3.2	4

#	Article	IF	CITATIONS
55	Titelbild: Squalenyl Hydrogen Sulfate Nanoparticles for Simultaneous Delivery of Tobramycin and an Alkylquinolone Quorum Sensing Inhibitor Enable the Eradication of ⟨i⟩P.â€aeruginosa⟨ i⟩ Biofilm Infections (Angew. Chem. 26/2020). Angewandte Chemie, 2020, 132, 10285-10285.	1.6	0
56	Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 151, 61-72.	2.0	17
57	Modulating the Barrier Function of Human Alveolar Epithelial (hAELVi) Cell Monolayers as a Model of Inflammation. ATLA Alternatives To Laboratory Animals, 2020, 48, 252-267.	0.7	8
58	Safety assessment of excipients (SAFE) for orally inhaled drug products. ALTEX: Alternatives To Animal Experimentation, 2020, 37, 275-286.	0.9	7
59	OCTN2-Mediated Acetyl-l-Carnitine Transport in Human Pulmonary Epithelial Cells In Vitro. Pharmaceutics, 2019, 11, 396.	2.0	11
60	Preferential uptake of chitosan-coated PLGA nanoparticles by primary human antigen presenting cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 21, 102073.	1.7	33
61	Mechanistic profiling of the release kinetics of siRNA from lipidoid-polymer hybrid nanoparticles in vitro and in vivo after pulmonary administration. Journal of Controlled Release, 2019, 310, 82-93.	4.8	33
62	Bioinspired Liposomes for Oral Delivery of Colistin to Combat Intracellular Infections by <i>Salmonella enterica </i> . Advanced Healthcare Materials, 2019, 8, e1900564.	3.9	45
63	Capturing the Onset of Bacterial Pulmonary Infection in Aciniâ€Onâ€Chips. Advanced Biology, 2019, 3, e1900026.	3.0	30
64	Macro- and Microrheological Properties of Mucus Surrogates in Comparison to Native Intestinal and Pulmonary Mucus. Biomacromolecules, 2019, 20, 3504-3512.	2.6	45
65	Challenges and strategies in drug delivery systems for treatment of pulmonary infections. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 144, 110-124.	2.0	95
66	Advanced in vitro lung-on-chip platforms for inhalation assays: From prospect to pipeline. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 144, 11-17.	2.0	53
67	Cellular and Non-cellular Barriers to Particle Transport Across the Lungs. Nanoscience and Technology, 2019, , 171-189.	1.5	0
68	Triple co-culture of human alveolar epithelium, endothelium and macrophages for studying the interaction of nanocarriers with the air-blood barrier. Acta Biomaterialia, 2019, 91, 235-247.	4.1	48
69	Preparation, characterisation andin vitroantibacterial property of ciprofloxacin-loaded nanostructured lipid carrier for treatment ofBacillus subtilisinfection. Journal of Microencapsulation, 2019, 36, 32-42.	1.2	4
70	The synergistic effect of chlorotoxin-mApoE in boosting drug-loaded liposomes across the BBB. Journal of Nanobiotechnology, 2019, 17, 115.	4.2	20
71	Vibrational spectroscopic imaging and live cell video microscopy for studying differentiation of primary human alveolar epithelial cells. Journal of Biophotonics, 2019, 12, e201800052.	1.1	6
72	Aspherical and Spherical InvA497-Functionalized Nanocarriers for Intracellular Delivery of Anti-Infective Agents. Pharmaceutical Research, 2019, 36, 22.	1.7	15

#	Article	IF	Citations
73	Lung-on-a-chip with a biological, stretchable membrane: New generation of in-vitro air-blood barrier model. , 2019, , .		o
74	Polysaccharide Submicrocarrier for Improved Pulmonary Delivery of Poorly Soluble Anti-infective Ciprofloxacin: Preparation, Characterization, and Influence of Size on Cellular Uptake. Molecular Pharmaceutics, 2018, 15, 1081-1096.	2.3	19
75	A miRNA181a/NFAT5 axis links impaired T cell tolerance induction with autoimmune type 1 diabetes. Science Translational Medicine, 2018, 10, .	5.8	49
76	The role of mucus on drug transport and its potential to affect therapeutic outcomes. Advanced Drug Delivery Reviews, 2018, 124, 82-97.	6.6	218
77	Murine Alveolar Epithelial Cells and Their Lentivirus-mediated Immortalisation. ATLA Alternatives To Laboratory Animals, 2018, 46, 73-89.	0.7	O
78	Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis. Scientific Reports, 2018, 8, 16776.	1.6	59
79	Human airway mucus alters susceptibility of Pseudomonas aeruginosa biofilms to tobramycin, but not colistin. Journal of Antimicrobial Chemotherapy, 2018, 73, 2762-2769.	1.3	39
80	Kinetics of mRNA delivery and protein translation in dendritic cells using lipid-coated PLGA nanoparticles. Journal of Nanobiotechnology, 2018, 16, 72.	4.2	49
81	Medium throughput breathing human primary cell alveolus-on-chip model. Scientific Reports, 2018, 8, 14359.	1.6	132
82	Can lifecycle management safeguard innovation in the pharmaceutical industry?. Drug Discovery Today, 2018, 23, 1962-1973.	3.2	7
83	Extracellular vesicles protect glucuronidase model enzymes during freeze-drying. Scientific Reports, 2018, 8, 12377.	1.6	65
84	Combining MucilAirâ,, $^{\circ}$ and VitrocellÂ $^{\circ}$ Powder Chamber for the In Vitro Evaluation of Nasal Ointments in the Context of Aerosolized Pollen. Pharmaceutics, 2018, 10, 56.	2.0	12
85	Starch-Chitosan Polyplexes: A Versatile Carrier System for Anti-Infectives and Gene Delivery. Polymers, 2018, 10, 252.	2.0	32
86	Farnesylated Glycol Chitosan as a Platform for Drug Delivery: Synthesis, Characterization, and Investigation of Mucus–Particle Interactions. Biomacromolecules, 2018, 19, 3489-3501.	2.6	33
87	<i>In Vitro</i> Model of the Gram-Negative Bacterial Cell Envelope for Investigation of Anti-Infective Permeation Kinetics. ACS Infectious Diseases, 2018, 4, 1188-1196.	1.8	20
88	Towards Standardized Dissolution Techniques for In Vitro Performance Testing of Dry Powder Inhalers. Dissolution Technologies, 2018, 25, 6-18.	0.2	20
89	Co-culture of human alveolar epithelial (hAELVi) and macrophage (THP-1) cell lines. ALTEX: Alternatives To Animal Experimentation, 2018, 35, 211-222.	0.9	55
90	A Model for the Transient Subdiffusive Behavior of Particles in Mucus. Biophysical Journal, 2017, 112, 172-179.	0.2	25

#	Article	IF	Citations
91	Cell and tissue-based in vitro models for improving the development of oral inhalation drug products. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 118, 73-78.	2.0	22
92	Barriers and motivations for non-invasive drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 118, 1-2.	2.0	0
93	Expression and Activity of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Distal Lung Epithelial Cells In Vitro. Pharmaceutical Research, 2017, 34, 2477-2487.	1.7	16
94	Basic Mathematics in Skin Absorption. , 2017, , 3-25.		2
95	Nanoencapsulation of a glucocorticoid improves barrier function and anti-inflammatory effect on monolayers of pulmonary epithelial cell lines. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119, 1-10.	2.0	7
96	Modelling the bronchial barrier in pulmonary drug delivery: A human bronchial epithelial cell line supplemented with human tracheal mucus. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 118, 79-88.	2.0	29
97	A foam model highlights the differences of the macro- and microrheology of respiratory horse mucus. Journal of the Mechanical Behavior of Biomedical Materials, 2017, 71, 216-222.	1.5	13
98	Diverse Applications of Nanomedicine. ACS Nano, 2017, 11, 2313-2381.	7. 3	976
99	Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119, 361-371.	2.0	30
100	Tracing molecular and structural changes upon mucolysis with N-acetyl cysteine in human airway mucus. International Journal of Pharmaceutics, 2017, 533, 373-376.	2.6	23
101	Biodegradable starch derivatives with tunable charge densityâ€"synthesis, characterization, and transfection efficiency. Drug Delivery and Translational Research, 2017, 7, 252-258.	3.0	8
102	Calcifediol-loaded liposomes for local treatment of pulmonary bacterial infections. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 118, 62-67.	2.0	22
103	The breathing lung-on-chip model for routine laboratory application. Toxicology Letters, 2017, 280, S272.	0.4	0
104	Lung alveoli array-on-chip with a bioartificial membrane. Toxicology Letters, 2017, 280, S277.	0.4	1
105	Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 117, 363-371.	2.0	100
106	Human Native and Reconstructed Skin Preparations for In Vitro Penetration and Permeation Studies. , $2017, 185-203$.		0
107	Exploring the susceptibility of P. aeruginosa biofilms in human mucus towards tobramycin treatment. , 2017, , .		0
108	A 3D co-culture of three human cell lines to model the inflamed intestinal mucosa for safety testing of nanomaterials. Nanotoxicology, 2016, 10, 1-10.	1.6	80

#	Article	IF	CITATIONS
109	Sustained-release liquisolid compact tablets containing artemether-lumefantrine as alternate-day regimen for malaria treatment to improve patient compliance. International Journal of Nanomedicine, 2016, Volume 11, 6365-6378.	3.3	8
110	Autologous Co-culture of Primary Human Alveolar Macrophages and Epithelial Cells for Investigating Aerosol Medicines. Part I: Model Characterisation. ATLA Alternatives To Laboratory Animals, 2016, 44, 337-347.	0.7	17
111	Autologous Co-culture of Primary Human Alveolar Macrophages and Epithelial Cells for Investigating Aerosol Medicines. Part II: Evaluation of IL-10-loaded Microparticles for the Treatment of Lung Inflammation. ATLA Alternatives To Laboratory Animals, 2016, 44, 349-360.	0.7	13
112	Penetration of topically applied nanocarriers into the hair follicles of dog and rat dorsal skin and porcine ear skin. Veterinary Dermatology, 2016, 27, 256.	0.4	13
113	New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy. Current Topics in Microbiology and Immunology, 2016, 398, 207-234.	0.7	16
114	IL-17A-mediated expression of epithelial IL-17C promotes inflammation during acute <i>Pseudomonas aeruginosa</i> pneumonia. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2016, 311, L1015-L1022.	1.3	38
115	Invasin-functionalized liposome nanocarriers improve the intracellular delivery of anti-infective drugs. RSC Advances, 2016, 6, 41622-41629.	1.7	12
116	Self-Assembly and Shape Control of Hybrid Nanocarriers Based on Calcium Carbonate and Carbon Nanodots. Chemistry of Materials, 2016, 28, 3796-3803.	3.2	18
117	In vitro models for evaluating safety and efficacy of novel technologies for skin drug delivery. Journal of Controlled Release, 2016, 242, 89-104.	4.8	55
118	miRNA92a targets KLF2 and the phosphatase PTEN signaling to promote human T follicular helper precursors in T1D islet autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6659-E6668.	3.3	50
119	Different macro- and micro-rheological properties of native porcine respiratory and intestinal mucus. International Journal of Pharmaceutics, 2016, 510, 164-167.	2.6	13
120	Design of Polyamine-Grafted Starches for Nucleotide Analogue Delivery: In Vitro Evaluation of the Anticancer Activity. Bioconjugate Chemistry, 2016, 27, 2431-2440.	1.8	10
121	The bacterial cell envelope as delimiter of anti-infective bioavailability – An in vitro permeation model of the Gram-negative bacterial inner membrane. Journal of Controlled Release, 2016, 243, 214-224.	4.8	25
122	Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16-17th, 2015 in Baltimore, MD. AAPS Open, 2016, 2, .	0.4	73
123	Impact of PEG and PEG- b -PAGE modified PLGA on nanoparticle formation, protein loading and release. International Journal of Pharmaceutics, 2016, 500, 187-195.	2.6	36
124	Tight junctions form a barrier in porcine hair follicles. European Journal of Cell Biology, 2016, 95, 89-99.	1.6	20
125	Influence of agglomeration and specific lung lining lipid/protein interaction on short-term inhalation toxicity. Nanotoxicology, 2016, 10, 970-980.	1.6	55
126	Size-Limited Penetration of Nanoparticles into Porcine Respiratory Mucus after Aerosol Deposition. Biomacromolecules, 2016, 17, 1536-1542.	2.6	114

#	Article	IF	Citations
127	Anti-infectives in Drug Deliveryâ€"Overcoming the Gram-Negative Bacterial Cell Envelope. Current Topics in Microbiology and Immunology, 2016, 398, 475-496.	0.7	9
128	The effect of polymer size and charge of molecules on permeation through synovial membrane and accumulation in hyaline articular cartilage. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 101, 126-136.	2.0	31
129	Antigen delivery via hydrophilic PEG- b -PAGE- b -PLGA nanoparticles boosts vaccination induced T cell immunity. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 102, 20-31.	2.0	47
130	Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosaâ€"Pharmaceutical Characterization and Fluorescence Imaging. Pharmaceutical Research, 2016, 33, 1085-1092.	1.7	65
131	Nanocarriers for optimizing the balance between interfollicular permeation and follicular uptake of topically applied clobetasol to minimize adverse effects. Journal of Controlled Release, 2016, 223, 207-214.	4.8	58
132	Dual flow bioreactor with ultrathin microporous TEER sensing membrane for evaluation of nanoparticle toxicity. Sensors and Actuators B: Chemical, 2016, 223, 440-446.	4.0	8
133	Human alveolar epithelial cells expressing tight junctions to model the air-blood barrier. ALTEX: Alternatives To Animal Experimentation, 2016, 33, 251-60.	0.9	80
134	Calcium Phosphate System for Gene Delivery: Historical Background and Emerging Opportunities. Current Pharmaceutical Design, 2016, 22, 1529-1533.	0.9	32
135	Polyester Particles for Drug Delivery to the Skin: Local and Systemic Applications. , 2016, , 353-377.		0
136	LSC Abstract $\hat{a} \in Modeling$ the air-blood barrier in healthy and disease state to evaluate safety and efficacy of inhaled (nano)medicines., 2016,,.		0
137	<i>In vivo</i> genome editing using nuclease-encoding mRNA corrects SP-B deficiency., 2016, , .		0
138	In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency. Nature Biotechnology, 2015, 33, 584-586.	9.4	113
139	Semi-Automated Nanoprecipitation-System—An Option for Operator Independent, Scalable and Size Adjustable Nanoparticle Synthesis. Pharmaceutical Research, 2015, 32, 1859-1863.	1.7	23
140	Dimethylaminoethyl methacrylate copolymer-siRNA nanoparticles for silencing a therapeutically relevant gene in macrophages. MedChemComm, 2015, 6, 691-701.	3.5	10
141	P-glycoprotein interactions of novel psychoactive substances – Stimulation of ATP consumption and transport across Caco-2 monolayers. Biochemical Pharmacology, 2015, 94, 220-226.	2.0	27
142	Expression and function of the epithelial sodium channel \hat{l} -subunit in human respiratory epithelial cells in vitro. Pflugers Archiv European Journal of Physiology, 2015, 467, 2257-2273.	1.3	12
143	A Design of Experiment Study of Nanoprecipitation and Nano Spray Drying as Processes to Prepare PLGA Nano- and Microparticles with Defined Sizes and Size Distributions. Pharmaceutical Research, 2015, 32, 2609-24.	1.7	40
144	Squalenoylation of Chitosan: A Platform for Drug Delivery?. Biomacromolecules, 2015, 16, 2930-2939.	2.6	28

#	Article	IF	Citations
145	Solid Phase Extraction as an Innovative Separation Method for Measuring Free and Entrapped Drug in Lipid Nanoparticles. Pharmaceutical Research, 2015, 32, 3999-4009.	1.7	25
146	Mono- and Cocultures of Bronchial and Alveolar Epithelial Cells Respond Differently to Proinflammatory Stimuli and Their Modulation by Salbutamol and Budesonide. Molecular Pharmaceutics, 2015, 12, 2625-2632.	2.3	16
147	Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections. Pharmaceutical Research, 2015, 32, 3850-3861.	1.7	15
148	A strategy for in-silico prediction of skin absorption in man. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 68-76.	2.0	11
149	Focused Ultrasound as a Scalable and Contact-Free Method to Manufacture Protein-Loaded PLGA Nanoparticles. Pharmaceutical Research, 2015, 32, 2995-3006.	1.7	13
150	Inverse micellar sugar glass (IMSG) nanoparticles for transfollicular vaccination. Journal of Controlled Release, 2015, 206, 140-152.	4.8	36
151	Macrophage uptake of cylindrical microparticles investigated with correlative microscopy. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 151-155.	2.0	19
152	Transfection System of Amino-Functionalized Calcium Phosphate Nanoparticles: In Vitro Efficacy, Biodegradability, and Immunogenicity Study. ACS Applied Materials & Samp; Interfaces, 2015, 7, 5124-5133.	4.0	22
153	Biological barriers $\hat{a}\in$ Advanced drug delivery, in vitro modelling, and their implications for infection research. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 95, 1-2.	2.0	2
154	Not just for tumor targeting: unmet medical needs and opportunities for nanomedicine. Nanomedicine, 2015, 10, 3147-3166.	1.7	23
155	Organic cation transporter function in different in vitro models of human lung epithelium. European Journal of Pharmaceutical Sciences, 2015, 80, 82-88.	1.9	15
156	Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/neuby human dendritic cells. Oncolmmunology, 2015, 4, e1047585.	2.1	9
157	Bacteriomimetic invasin-functionalized nanocarriers for intracellular delivery. Journal of Controlled Release, 2015, 220, 414-424.	4.8	23
158	Proteomic and Lipidomic Analysis of Nanoparticle Corona upon Contact with Lung Surfactant Reveals Differences in Protein, but Not Lipid Composition. ACS Nano, 2015, 9, 11872-11885.	7.3	164
159	Preclinical safety and efficacy models for pulmonary drug delivery of antimicrobials with focus on in vitro models. Advanced Drug Delivery Reviews, 2015, 85, 44-56.	6.6	44
160	Efficient nanoparticle-mediated needle-free transcutaneous vaccination via hair follicles requires adjuvantation. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 147-154.	1.7	38
161	The buccal mucosa as a route for TiO ₂ nanoparticle uptake. Nanotoxicology, 2015, 9, 253-261.	1.6	45
162	In Vitro–In Vivo Correlation: Shades on Some Non-Conventional Dosage Forms. Dissolution Technologies, 2015, 22, 19-22.	0.2	6

#	Article	IF	CITATIONS
163	Miniature In Vitro Dissolution Testing of Powders for Inhalation. Dissolution Technologies, 2015, 22, 40-51.	0.2	13
164	Non-animal models of epithelial barriers (skin, intestine and lung) in research, industrial applications and regulatory toxicology. ALTEX: Alternatives To Animal Experimentation, 2015, 32, 327-378.	0.9	108
165	Nanoencapsulation in Lipid-Core Nanocapsules Controls Mometasone Furoate Skin Permeability Rate and Its Penetration to the Deeper Skin Layers. Skin Pharmacology and Physiology, 2014, 27, 217-217.	1.1	31
166	Overcoming the pulmonary barrier: new insights to improve the efficiency of inhaled therapeutics. European Journal of Nanomedicine, 2014, 6, .	0.6	42
167	<i>In vitro</i> toxicological screening of nanoparticles on primary human endothelial cells and the role of flow in modulating cell response. Nanotoxicology, 2014, 8, 697-708.	1.6	48
168	Quantification of nanoparticle uptake into hair follicles in pig ear and human forearm. Journal of Controlled Release, 2014, 179, 25-32.	4.8	98
169	Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. Journal of Controlled Release, 2014, 183, 167-177.	4.8	114
170	Non-invasive determination of cellular oxygen consumption as novel cytotoxicity assay for nanomaterials. Nanotoxicology, 2014, 8, 50-60.	1.6	3
171	The Cell Line NCl-H441 Is a Useful <i>in Vitro</i> Model for Transport Studies of Human Distal Lung Epithelial Barrier. Molecular Pharmaceutics, 2014, 11, 995-1006.	2.3	105
172	Antibiotic-free nanotherapeutics: Ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. Journal of Controlled Release, 2014, 192, 131-140.	4.8	160
173	Transfollicular delivery takes root: the future for vaccine design?. Expert Review of Vaccines, 2014, 13, 5-7.	2.0	22
174	Dissolution Testing of Powders for Inhalation: Influence of Particle Deposition and Modeling of Dissolution Profiles. Pharmaceutical Research, 2014, 31, 3211-3224.	1.7	41
175	Design of Starch- <i>graft</i> -PEI Polymers: An Effective and Biodegradable Gene Delivery Platform. Biomacromolecules, 2014, 15, 1753-1761.	2.6	56
176	Development of artemether-loaded nanostructured lipid carrier (NLC) formulation for topical application. International Journal of Pharmaceutics, 2014, 477, 208-217.	2.6	73
177	Crystal suspensions of poorly soluble peptides for intra-articular application: A novel approach for biorelevant assessment of their in vitro release. International Journal of Pharmaceutics, 2014, 461, 46-53.	2.6	10
178	Characterization and evaluation of a modified PVPA barrier in comparison to Caco-2 cell monolayers for combined dissolution and permeation testing. Journal of Controlled Release, 2014, 175, 79-86.	4.8	24
179	Statistical Comparison of Dissolution Profiles to Predict the Bioequivalence of Extended Release Formulations. AAPS Journal, 2014, 16, 791-801.	2.2	9
180	Carrier interactions with the biological barriers of the lung: Advanced in vitro models and challenges for pulmonary drug delivery. Advanced Drug Delivery Reviews, 2014, 75, 129-140.	6.6	100

#	Article	IF	CITATIONS
181	One-Step Synthesis of Nanosized and Stable Amino-Functionalized Calcium Phosphate Particles for DNA Transfection. Chemistry of Materials, 2013, 25, 3667-3674.	3.2	32
182	From the Structure of the Skin Barrier and Dermal Formulations to in vitro Transport Models for Skin Absorption: Skin Research in the Netherlands and in Germany. Skin Pharmacology and Physiology, 2013, 26, 317-330.	1.1	10
183	PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 578-586.	2.0	106
184	Non-invasive delivery of nanoparticles to hair follicles: A perspective for transcutaneous immunization. Vaccine, 2013, 31, 3442-3451.	1.7	69
185	Permutation Test (PT) and Tolerated Difference Test (TDT): Two new, robust and powerful nonparametric tests for statistical comparison of dissolution profiles. International Journal of Pharmaceutics, 2013, 441, 458-467.	2.6	10
186	Nano- and microscaled particles for drug targeting to inflamed intestinal mucosaâ€"A first in vivo study in human patients. Journal of Controlled Release, 2013, 165, 139-145.	4.8	183
187	Modeling the human skin barrier—Towards a better understanding of dermal absorption. Advanced Drug Delivery Reviews, 2013, 65, 149-151.	6.6	8
188	Nanoparticle Geometry and Surface Orientation Influence Mode of Cellular Uptake. ACS Nano, 2013, 7, 1961-1973.	7.3	287
189	Crossing biological barriers for advanced drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 84, 239-241.	2.0	19
190	Improved input parameters for diffusion models of skin absorption. Advanced Drug Delivery Reviews, 2013, 65, 251-264.	6.6	40
191	Pulmonary drug delivery: from generating aerosols to overcoming biological barriersâ€"therapeutic possibilities and technological challenges. Lancet Respiratory Medicine,the, 2013, 1, 402-413.	5.2	203
192	Pulmonary surfactant is indispensable in order to simulate the in vivo situation. Particle and Fibre Toxicology, 2013, 10, 6.	2.8	35
193	Mucus as a barrier to lipophilic drugs. International Journal of Pharmaceutics, 2013, 453, 56-64.	2.6	217
194	Finite dose skin mass balance including the lateral part: Comparison between experiment, pharmacokinetic modeling and diffusion models. Journal of Controlled Release, 2013, 165, 119-128.	4.8	22
195	Nanomedicines for the treatment of inflammatory bowel diseases. European Journal of Nanomedicine, $2013, 5, .$	0.6	8
196	Particle based vaccine formulations for transcutaneous immunization. Human Vaccines and Immunotherapeutics, 2013, 9, 1950-1955.	1.4	17
197	Biopharmaceutical <i>in vitro</i> characterization of CPZEN-45, a drug candidate for inhalation therapy of tuberculosis. Therapeutic Delivery, 2013, 4, 915-923.	1.2	36
198	In Situ Drug Release Monitoring with a Fiber-Optic System: Overcoming Matrix Interferences Using Derivative Spectrophotometry. Dissolution Technologies, 2013, 20, 15-19.	0.2	10

#	Article	IF	Citations
199	Characterization and evaluation of \hat{l}^2 -glucan formulations as injectable implants for protein and peptide delivery. Drug Development and Industrial Pharmacy, 2012, 38, 1337-1343.	0.9	2
200	Isolation, Cultivation, and Application of Human Alveolar Epithelial Cells. Methods in Molecular Biology, 2012, 806, 31-42.	0.4	33
201	Atomic Force Microscopy and Analytical Ultracentrifugation for Probing Nanomaterial Protein Interactions. ACS Nano, 2012, 6, 4603-4614.	7.3	69
202	Treatment of lung cancer via telomerase inhibition: Self-assembled nanoplexes versus polymeric nanoparticles as vectors for 2′-O-Methyl-RNA. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 80, 478-489.	2.0	28
203	Pulmonary delivery and tissue distribution of aerosolized antisense 2′-O-Methyl RNA containing nanoplexes in the isolated perfused and ventilated rat lung. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 478-485.	2.0	18
204	Optical tweezers reveal relationship between microstructure and nanoparticle penetration of pulmonary mucus. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 18355-18360.	3.3	160
205	Cellular delivery of polynucleotides by cationic cyclodextrin polyrotaxanes. Journal of Controlled Release, 2012, 164, 387-393.	4.8	38
206	The Interplay of Lung Surfactant Proteins and Lipids Assimilates the Macrophage Clearance of Nanoparticles. PLoS ONE, 2012, 7, e40775.	1.1	123
207	Dissolution Techniques for In Vitro Testing of Dry Powders for Inhalation. Pharmaceutical Research, 2012, 29, 2157-2166.	1.7	75
208	Process optimization and biocompatibility of cell carriers suitable for automated magnetic manipulation. Acta Biomaterialia, 2012, 8, 1239-1247.	4.1	0
209	Influence of the application area on finite dose permeation in relation to drug type applied. Experimental Dermatology, 2012, 21, 233-235.	1.4	11
210	Soluplus \hat{A}^{\otimes} as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. European Journal of Pharmaceutical Sciences, 2012, 45, 336-343.	1.9	201
211	Nanoparticles for transcutaneous vaccination. Microbial Biotechnology, 2012, 5, 156-167.	2.0	54
212	Mucociliary clearance of micro- and nanoparticles is independent of size, shape and chargeâ€"an ex vivo and in silico approach. Journal of Controlled Release, 2012, 159, 128-134.	4.8	79
213	Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. Journal of Controlled Release, 2012, 161, 235-246.	4.8	206
214	A Hydrophobic Starch Polymer for Nanoparticleâ€Mediated Delivery of Docetaxel. Macromolecular Bioscience, 2012, 12, 184-194.	2.1	55
215	Chapter 5.1. Nanostructures for Overcoming the Pulmonary Barriers: Physiological Considerations and Mechanistic Issues. RSC Drug Discovery Series, 2012, , 239-272.	0.2	4
216	Screening of budesonide nanoformulations for treatment of inflammatory bowel disease in an inflamed 3D cell-culture model. ALTEX: Alternatives To Animal Experimentation, 2012, 29, 275-285.	0.9	54

#	Article	IF	CITATIONS
217	A new Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) to evaluate pulmonary drug absorption for metered dose dry powder formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 132-138.	2.0	45
218	Interaction of metal oxide nanoparticles with lung surfactant protein A. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 376-383.	2.0	71
219	An in vitro triple cell co-culture model with primary cells mimicking the human alveolar epithelial barrier. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 398-406.	2.0	113
220	Biological barriers – A need for novel tools in nanotoxicology and nanomedicine. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 337.	2.0	7
221	Improved photostability and reduced skin permeation of tretinoin: Development of a semisolid nanomedicine. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79, 95-101.	2.0	109
222	1223 POSTER Enhanced Cellular Delivery of Idarubicin by Surface Modification of Propyl Starch Nanoparticles Employing Pteroic Acid Conjugated Polyvinyl Alcohol. European Journal of Cancer, 2011, 47, S151.	1.3	0
223	1224 POSTER Docetaxel Delivery Mediated by Nanoparticles of Novel Hydrophobic Starch. European Journal of Cancer, 2011, 47, S151-S152.	1.3	0
224	The molecular basis of bioadhesion. Journal of Pharmacy and Pharmacology, 2011, 50, 11-11.	1.2	1
225	Computational fluid dynamics of nanoparticle disposition in the airways: mucus interactions and mucociliary clearance. Computing and Visualization in Science, 2011, 14, 301-308.	1.2	12
226	Finite dose skin penetration: a comparison of concentration-depth profiles from experiment and simulation. Computing and Visualization in Science, 2011, 14, 327-339.	1.2	12
227	Nano-Particulate Calcium Phosphate as a Gene Delivery System. , 2011, , .		1
228	Effects of the Mucoadhesive Polymer Polycarbophil on the Intestinal Absorption of a Peptide Drug in the Rat. Journal of Pharmacy and Pharmacology, 2011, 44, 402-407.	1.2	99
229	Uptake of nanoparticles by alveolar macrophages is triggered by surfactant protein A. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 690-693.	1.7	117
230	Selective follicular targeting by modification of the particle sizes. Journal of Controlled Release, 2011, 150, 45-48.	4.8	260
231	Tissue slice model of human lung cancer to investigate telomerase inhibition by nanoparticle delivery of antisense $2\hat{a}\in^2$ -O-methyl-RNA. International Journal of Pharmaceutics, 2011, 419, 33-42.	2.6	28
232	Enhanced cellular delivery of idarubicin by surface modification of propyl starch nanoparticles employing pteroic acid conjugated polyvinyl alcohol. International Journal of Pharmaceutics, 2011, 420, 147-155.	2.6	38
233	Propidium iodide labeling of nanoparticles as a novel tool for the quantification of cellular binding and uptake. Nanomedicine: Nanotechnology, Biology, and Medicine, 2011, 7, 410-419.	1.7	27
234	Templateâ€Assisted Polyelectrolyte Encapsulation of Nanoparticles into Dispersible, Hierarchically Nanostructured Microfibers. Advanced Materials, 2011, 23, 1376-1379.	11,1	40

#	Article	IF	Citations
235	Towards nanotechnology regulation – Publish the unpublishable. Nano Today, 2011, 6, 228-231.	6.2	16
236	Transport of Metal Oxide Nanoparticles Across Calu-3 Cell Monolayers Modelling the Air-Blood Barrier. EURO-NanoTox-Letters, 2011, 3, 1-10.	1.0	5
237	Multilayer Coating of Gold Nanoparticles with Drugâ^'Polymer Coadsorbates. Langmuir, 2010, 26, 16901-16908.	1.6	64
238	Wistar rat skin as surrogate for human skin in nortriptyline hydrochloride patch studies. International Journal of Pharmaceutics, 2010, 384, 137-139.	2.6	0
239	Calorimetric and spectrophotometric investigation of PLGA nanoparticles and their complex with DNA. Journal of Thermal Analysis and Calorimetry, 2010, 99, 337-348.	2.0	9
240	Nanoparticles made from novel starch derivatives for transdermal drug delivery. Journal of Controlled Release, 2010, 141, 85-92.	4.8	257
241	In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles. Journal of Controlled Release, 2010, 141, 101-107.	4.8	55
242	Telomerase as an emerging target to fight cancer — Opportunities and challenges for nanomedicine. Journal of Controlled Release, 2010, 146, 228-240.	4.8	50
243	Differential cell reaction upon Toll-like receptor 4 and 9 activation in human alveolar and lung interstitial macrophages. Respiratory Research, 2010, 11, 124.	1.4	83
244	Online monitoring of transepithelial electrical resistance (TEER) in an apparatus for combined dissolution and permeation testing. International Journal of Pharmaceutics, 2010, 392, 134-140.	2.6	23
245	The Pharmaceutical Aerosol Deposition Device on Cell Cultures (PADDOCC) <i>In Vitro</i> System: Design and Experimental Protocol. ATLA Alternatives To Laboratory Animals, 2010, 38, 285-295.	0.7	28
246	Infrared Densitometry: A Fast and Non-Destructive Method for Exact Stratum Corneum Depth Calculation for in vitro Tape-Stripping. Skin Pharmacology and Physiology, 2010, 23, 183-192.	1.1	47
247	Pulmonary Drug Delivery: Medicines for Inhalation. Handbook of Experimental Pharmacology, 2010, , 171-192.	0.9	22
248	Nanoparticle mediated delivery of 2′-O-methyl-RNA leads to efficient telomerase inhibition and telomere shortening in human lung cancer cells. Lung Cancer, 2010, 68, 346-354.	0.9	29
249	Cellular Responses after Exposure of Lung Cell Cultures to Secondary Organic Aerosol Particles. Environmental Science & Environmental Science & Enviro	4.6	56
250	Plant genetic factors for iron homeostasis affect iron bioavailability in Caco-2 cells. Food Research International, 2010, 43, 1661-1665.	2.9	2
251	A dynamic ratio of the $\hat{l}\pm +$ and $\hat{l}\pm \hat{a}^{*}$ isoforms of the tight junction protein ZO-1 is characteristic of Caco-2 cells and correlates with their degree of differentiation. Cell Biology International, 2010, 34, 669-678.	1.4	8
252	Drug Transport Across Pulmonary Epithelial Cell Monolayers: Effects of Particle Size, Apical Liquid Volume, and Deposition Technique. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, 119-127.	0.7	51

#	Article	IF	CITATIONS
253	Vitamin E TPGS P-Glycoprotein Inhibition Mechanism: Influence on Conformational Flexibility, Intracellular ATP Levels, and Role of Time and Site of Access. Molecular Pharmaceutics, 2010, 7, 642-651.	2.3	186
254	A Three-Dimensional Coculture of Enterocytes, Monocytes and Dendritic Cells To Model Inflamed Intestinal Mucosa in Vitro. Molecular Pharmaceutics, 2010, 7, 2103-2119.	2.3	179
255	Influence of Particle Size and Material Properties on Mucociliary Clearance from the Airways. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, 233-241.	0.7	78
256	Efficient Telomerase Inhibition in Human Non-small Cell Lung Cancer Cells by Liposomal Delivery of 2′-O-Methyl-RNA. Journal of Pharmaceutical Sciences, 2009, 98, 1765-1774.	1.6	13
257	The Role of Corneocytes in Skin Transport Revised—A Combined Computational and Experimental Approach. Pharmaceutical Research, 2009, 26, 1379-1397.	1.7	36
258	PLGA Nanoparticles Stabilized with Cationic Surfactant: Safety Studies and Application in Oral Delivery of Paclitaxel to Treat Chemical-Induced Breast Cancer in Rat. Pharmaceutical Research, 2009, 26, 2495-2503.	1.7	133
259	Relevance of the colloidal stability of chitosan/PLGA nanoparticles on their cytotoxicity profile. International Journal of Pharmaceutics, 2009, 381, 130-139.	2.6	149
260	Nortriptyline for smoking cessation: Release and human skin diffusion from patches. International Journal of Pharmaceutics, 2009, 378, 101-107.	2.6	16
261	Differentiation potential of human pancreatic stem cells for epithelial- and endothelial-like cell types. Annals of Anatomy, 2009, 191, 70-82.	1.0	3
262	The influence of chitosan content in cationic chitosan/PLGA nanoparticles on the delivery efficiency of antisense 2′-O-methyl-RNA directed against telomerase in lung cancer cells. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 358-369.	2.0	62
263	A novel cell compatible impingement system to study in vitro drug absorption from dry powder aerosol formulations. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 350-357.	2.0	41
264	Biological barriers and nanomedicine – Timely challenges in advanced drug delivery researchâ⁻†. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 287-288.	2.0	7
265	Hyaluronic Acid-Modified DOTAP/DOPE Liposomes for the Targeted Delivery of Anti-Telomerase siRNA to CD44-Expressing Lung Cancer Cells. Oligonucleotides, 2009, 19, 103-116.	2.7	90
266	In Vitro Systems for Studying Epithelial Transport of Macromolecules. Methods in Molecular Biology, 2009, 480, 151-164.	0.4	8
267	Inhalative nanomedicineâ€"Opportunities and challenges. Inhalation Toxicology, 2009, 21, 137-143.	0.8	48
268	Decomposition of the Telomere-Targeting agent BRACO19 in physiological media results in products with decreased inhibitory potential. International Journal of Pharmaceutics, 2008, 357, 6-14.	2.6	8
269	Embryonic Chicken Trachea as a New In Vitro Model for the Investigation of Mucociliary Particle Clearance in the Airways. AAPS PharmSciTech, 2008, 9, 521-527.	1.5	21
270	Models for Skin Absorption and Skin Toxicity Testing. , 2008, , 3-33.		19

#	Article	IF	CITATIONS
271	In-silico model of skin penetration based on experimentally determined input parameters. Part I: Experimental determination of partition and diffusion coefficients. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 352-367.	2.0	94
272	In-silico model of skin penetration based on experimentally determined input parameters. Part II: Mathematical modelling of in-vitro diffusion experiments. Identification of critical input parameters. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 68, 368-379.	2.0	70
273	Nortriptyline hydrochloride skin absorption: Development of a transdermal patch. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 588-596.	2.0	36
274	Not ready to use – overcoming pitfalls when dispersing nanoparticles in physiological media. Nanotoxicology, 2008, 2, 51-61.	1.6	148
275	Novel luminescence assay offers new possibilities for the risk assessment of silica nanoparticles. Nanotoxicology, 2008, 2, 243-251.	1.6	17
276	Influence of Human Skin Specimens Consisting of Different Skin Layers on the Result of in vitro Permeation Experiments. Skin Pharmacology and Physiology, 2008, 21, 81-88.	1.1	24
277	Pulmonary cell culture models to study the safety and efficacy of innovative aerosol medicines. Expert Opinion on Drug Delivery, 2008, 5, 641-652.	2.4	25
278	Naturally occurring reactive sulfur species, their activity against Caco-2 cells, and possible modes of biochemical action. Journal of Sulfur Chemistry, 2008, 29, 251-268.	1.0	26
279	A Comparative Evaluation of Corneal Epithelial Cell Cultures for Assessing Ocular Permeability. ATLA Alternatives To Laboratory Animals, 2008, 36, 33-44.	0.7	50
280	The Physicochemical Parameters of Marker Compounds and Vehicles for Use in In Vitro Percutaneous Absorption Studies. ATLA Alternatives To Laboratory Animals, 2008, 36, 189-200.	0.7	2
281	The Use of Reconstructed Human Epidermis for Skin Absorption Testing: Results of the Validation Study. ATLA Alternatives To Laboratory Animals, 2008, 36, 161-187.	0.7	193
282	Development and characterization of film forming polymeric solutions for skin drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 65, 111-121.	2.0	95
283	Permeability of the reconstructed human epidermis model Episkin® in comparison to various human skin preparationsâ~†. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 66, 127-134.	2.0	89
284	Permeability assessment for solid oral drug formulations based on Caco-2 monolayer in combination with a flow through dissolution cell. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 66, 286-295.	2.0	46
285	Nanoparticles – An efficient carrier for drug delivery into the hair follicles. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 66, 159-164.	2.0	488
286	Monolayers of porcine alveolar epithelial cells in primary culture as an in vitro model for drug absorption studies. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 66, 372-382.	2.0	22
287	Dexamethasone-loaded nanoparticle-coated microparticles: Correlation between in vitro drug release and drug transport across Caco-2 cell monolayers. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 18-30.	2.0	50
288	Mechanism of Inhibition of P-Glycoprotein Mediated Efflux by Vitamin E TPGS:  Influence on ATPase Activity and Membrane Fluidity. Molecular Pharmaceutics, 2007, 4, 465-474.	2.3	244

#	Article	IF	Citations
289	Expression of ABC-Transporters in Human Corneal Tissue and the Transformed Cell Line, HCE-T. Journal of Ocular Pharmacology and Therapeutics, 2007, 23, 172-181.	0.6	40
290	Coupling of Biotinâ^'(poly(ethylene glycol))amine to Poly(d,l-lactide-co-glycolide) Nanoparticles for Versatile Surface Modification. Bioconjugate Chemistry, 2007, 18, 1087-1094.	1.8	46
291	Conformational change of membrane proteins leads to shape changes of red blood cells. Bioelectrochemistry, 2007, 70, 122-126.	2.4	42
292	Automated measurement of permeation and dissolution of propranolol HCl tablets using sequential injection analysis. Analytica Chimica Acta, 2007, 581, 174-180.	2.6	23
293	Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine: Nanotechnology, Biology, and Medicine, 2007, 3, 173-183.	1.7	224
294	Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs. Journal of Controlled Release, 2007, 118, 196-203.	4.8	47
295	P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers. Cell and Tissue Research, 2007, 328, 77-84.	1.5	54
296	Multiphoton Microscopy for the Investigation of trans-cutaneous drug delivery. , 2007, , .		0
297	Influence of Nanoencapsulation on Human Skin Transport of Flufenamic Acid. Skin Pharmacology and Physiology, 2006, 19, 190-197.	1.1	133
298	Development of a fluorescence-based assay for screening of modulators of human Organic Anion Transporter 1B3 (OATP1B3). European Journal of Pharmaceutics and Biopharmaceutics, 2006, 62, 39-43.	2.0	38
299	TEWL measurements as a routine method for evaluating the integrity of epidermis sheets in static Franz type diffusion cells in vitro. Limitations shown by transport data testing. European Journal of Pharmaceutics and Biopharmaceutics, 2006, 63, 44-50.	2.0	69
300	Reconstructed Human Epidermis for Skin Absorption Testing: Results of the German Prevalidation Study. ATLA Alternatives To Laboratory Animals, 2006, 34, 283-294.	0.7	108
301	Effect of PEGylation on the Stability of Liposomes During Nebulisation and in Lung Surfactant. Journal of Nanoscience and Nanotechnology, 2006, 6, 3010-3016.	0.9	43
302	Multiphoton Microscopy for the Investigation of Dermal Penetration of Nanoparticle-Borne Drugs. Journal of Investigative Dermatology, 2006, 126, 2224-2233.	0.3	131
303	Assessment of mucoadhesion by a resonant mirror biosensor. International Journal of Pharmaceutics, 2006, 325, 75-81.	2.6	50
304	Biopharmaceutical Characterization of the Telomerase Inhibitor BRACO19. Pharmaceutical Research, 2006, 23, 1031-1037.	1.7	42
305	Porcine Alveolar Epithelial Cells in Primary Culture: Morphological, Bioelectrical and Immunocytochemical Characterization. Pharmaceutical Research, 2006, 23, 2078-2093.	1.7	28
306	Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o Cell and Tissue Research, 2006, 323, 405-415.	1.5	105

#	Article	IF	CITATIONS
307	Assessment of transport rates of proteins and peptides across primary human alveolar epithelial cell monolayers. European Journal of Pharmaceutical Sciences, 2006, 28, 196-203.	1.9	49
308	In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. European Journal of Pharmaceutical Sciences, 2006, 29, 367-374.	1.9	121
309	Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. Journal of Controlled Release, 2006, 111, 35-40.	4.8	165
310	Nanoparticles made of Fluorescence-Labelled Poly(L-lactide-co-glycolide): Preparation, Stability, and Biocompatibility. Journal of Nanoscience and Nanotechnology, 2006, 6, 3048-3056.	0.9	46
311	The Influence of Physicochemical Parameters on the Efficacy of Non-Viral DNA Transfection Complexes: A Comparative Study. Journal of Nanoscience and Nanotechnology, 2006, 6, 2776-2782.	0.9	34
312	Human Vascular Endothelial Cells in Primary Cell Culture for the Evaluation of Nanoparticle Bioadhesion. Journal of Nanoscience and Nanotechnology, 2006, 6, 3303-3309.	0.9	16
313	Comparison of bovine udder skin with human and porcine skin in percutaneous permeation experiments. ATLA Alternatives To Laboratory Animals, 2006, 34, 499-513.	0.7	46
314	Isolation and Culture of Human Alveolar Epithelial Cells. , 2005, 107, 207-216.		32
315	Preparation and characterization of chitosan and trimethyl-chitosanmodified poly-(Îμ-caprolactone) nanoparticles as DNA carriers. AAPS PharmSciTech, 2005, 6, E22-E30.	1.5	53
316	Optimization of the TRAP assay to evaluate specificity of telomerase inhibitors. Laboratory Investigation, 2005, 85, 1565-1569.	1.7	26
317	Laser interference lithography as a new and efficient technique for micropatterning of biopolymer surface. Biomaterials, 2005, 26, 2307-2312.	5.7	79
318	Estimation of paracellular conductance of primary rat alveolar epithelial cell monolayers. Journal of Applied Physiology, 2005, 98, 138-143.	1.2	11
319	Tissue Distribution of Moxaverine–Hydrochloride in the Rabbit Eye and Plasma. Journal of Ocular Pharmacology and Therapeutics, 2005, 21, 210-216.	0.6	15
320	Depletion of alveolar macrophages by clodronate-liposomes aggravates ischemia—reperfusion injury of the lung. Journal of Heart and Lung Transplantation, 2005, 24, 38-45.	0.3	50
321	Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 60, 295-303.	2.0	97
322	The human epidermis models EpiSkin®, SkinEthic® and EpiDerm®: An evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 60, 167-178.	2.0	297
323	Cell culture models and nanobiotechnology—contemporary topics in advanced drug delivery research. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 60, v-vi.	2.0	3
324	GALENOS Euro-PhD in Advanced Drug Delivery: an innovative European Postgraduate Certificate for young pharmaceutical scientists, funded by the EU Marie Curie EST programme. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 60, 315-316.	2.0	0

#	Article	IF	Citations
325	Salbutamol is actively absorbed across human bronchial epithelial cell layers. Pulmonary Pharmacology and Therapeutics, 2005, 18, 165-170.	1.1	62
326	Nanoparticles as Non-Viral Transfection Agents. , 2005, , 319-342.		0
327	Cell Culture Models of the Respiratory Tract Relevant to Pulmonary Drug Delivery. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2005, 18, 137-182.	1.2	135
328	Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. Journal of Controlled Release, 2004, 97, 321-332.	4.8	110
329	Lectins and glycoconjugates in drug delivery and targeting. Advanced Drug Delivery Reviews, 2004, 56, 419-420.	6.6	23
330	Computational modeling of the sugar–lectin interaction. Advanced Drug Delivery Reviews, 2004, 56, 437-457.	6.6	43
331	Lectin-mediated drug targeting: history and applications. Advanced Drug Delivery Reviews, 2004, 56, 425-435.	6.6	363
332	Preparation and characterization of cationic PLGA nanospheres as DNA carriers. Biomaterials, 2004, 25, 1771-1777.	5.7	432
333	Cationic Poly(lactide-<1>co 1 -glycolide) Nanoparticles as Efficient <1> in vivo 1 Gene Transfection Agents. Journal of Nanoscience and Nanotechnology, 2004, 4, 990-994.	0.9	72
334	Cationic Silica Nanoparticles as Gene Carriers: Synthesis, Characterization and Transfection Efficiency <i>In vitro</i> and <i>In vivo</i> . Journal of Nanoscience and Nanotechnology, 2004, 4, 876-881.	0.9	177
335	Reoxygenation results in cell death of human alveolar epithelial cells. Journal of Heart and Lung Transplantation, 2004, 23, 1198-1204.	0.3	3
336	Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. European Journal of Pharmaceutics and Biopharmaceutics, 2004, 57, 155-162.	2.0	129
337	16HBE140- human bronchial epithelial cell layers express P-glycoprotein, lung resistance-related protein, and caveolin-1. Pharmaceutical Research, 2003, 20, 545-551.	1.7	60
338	Large porous particle impingement on lung epithelial cell monolayers-toward improved particle characterization in the lung. Pharmaceutical Research, 2003, 20, 788-796.	1.7	108
339	Differentiation of human alveolar epithelial cells in primary culture: morphological characterization and synthesis of caveolin-1 and surfactant protein-C. Cell and Tissue Research, 2003, 311, 31-45.	1.5	141
340	Stabilisation by freeze-drying of cationically modified silica nanoparticles for gene delivery. International Journal of Pharmaceutics, 2003, 266, 51-60.	2.6	121
341	Laser ablation patterning by interference induces directional cell growth. IEEE Transactions on Nanobioscience, 2003, 2, 138-145.	2.2	37
342	pH profiles in human skin: influence of two in vitro test systems for drug delivery testing. European Journal of Pharmaceutics and Biopharmaceutics, 2003, 55, 57-65.	2.0	82

#	Article	IF	Citations
343	Chemical crosslinking of urokinase to pulmonary surfactant protein B for targeting alveolar fibrin. Thrombosis and Haemostasis, 2003, 89, 53-64.	1.8	17
344	Drug Absorption by the Respiratory Mucosa: Cell Culture Models and Particulate Drug Carriers. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2002, 15, 131-139.	1.2	77
345	Carrier systems for the treatment of inflammatory bowel disease. Drugs of the Future, 2002, 27, 961.	0.0	16
346	Chemical Coupling of a Monoclonal Antisurfactant Protein-B Antibody to Human Urokinase for Targeting Surfactant-Incorporating Alveolar Fibrin. Bioconjugate Chemistry, 2002, 13, 804-811.	1.8	9
347	Self-Assembly of β-Lactoglobulin and Acacia Gum in Aqueous Solvent: Structure and Phase-Ordering Kinetics. Langmuir, 2002, 18, 10323-10333.	1.6	86
348	Wet chemical modification of PTFE implant surfaces with a specific cell adhesion molecule. Chemical Communications, 2002, , 2568-2569.	2.2	23
349	Developments in the area of bioadhesive drug delivery systems. Expert Opinion on Biological Therapy, 2002, 2, 287-298.	1.4	79
350	Lectin-mediated Drug Delivery: Discrimination Between Cytoadhesion and Cytoinvasion and Evidence for Lysosomal Accumulation of Wheat Germ Agglutinin in the Caco-2 Model. Journal of Drug Targeting, 2002, 10, 439-448.	2.1	35
351	Correlation between Stratum Corneum/Waterâ€Partition Coefficient and Amounts of Flufenamic Acid Penetrated into the Stratum Corneum. Journal of Pharmaceutical Sciences, 2002, 91, 1915-1921.	1.6	16
352	Influence of apical fluid volume on the development of functional intercellular junctions in the human epithelial cell line 16HBE14o-: implications for the use of this cell line as an in vitro model for bronchial drug absorption studies. Cell and Tissue Research, 2002, 308, 391-400.	1.5	111
353	Human Skin Penetration of Flufenamic Acid: In Vivo/In Vitro Correlation (Deeper Skin Layers) for Skin Samples from the Same Subject. Journal of Investigative Dermatology, 2002, 118, 540-544.	0.3	40
354	Lectin-sugar interaction. FEBS Journal, 2002, 269, 1518-1524.	0.2	26
355	Models of the alveolar epithelium. , 2002, , 189-210.		4
356	Human skin and skin equivalents to study dermal penetration and permeation., 2002,, 289-309.		2
357	Confocal and two-photon fluorescence microscopy. , 2002, , 378-391.		0
358	Studying cellular binding and uptake of bioadhesive lectins. , 2002, , 62-93.		0
359	Influences of process parameters on preparation of microparticle used as a carrier system for O - 3 unsaturated fatty acid ethyl esters used in supplementary nutrition. Journal of Microencapsulation, 2001, 18, 347-357.	1.2	90
360	Study of \hat{l}^2 -lactoglobulin/acacia gum complex coacervation by diffusing-wave spectroscopy and confocal scanning laser microscopy. Colloids and Surfaces B: Biointerfaces, 2001, 20, 267-280.	2.5	97

#	Article	IF	CITATIONS
361	Systemic delivery of cetrorelix to rats by a new aerosol delivery system. Pharmaceutical Research, 2001, 18, 771-779.	1.7	9
362	Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharmaceutical Research, 2001, 18, 788-793.	1.7	419
363	Design of rolipram-loaded nanoparticles: comparison of two preparation methods. Journal of Controlled Release, 2001, 71, 297-306.	4.8	68
364	Interrelation of permeation and penetration parameters obtained from in vitro experiments with human skin and skin equivalents. Journal of Controlled Release, 2001, 75, 283-295.	4.8	81
365	Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. Journal of Controlled Release, 2001, 77, 345-355.	4.8	172
366	Lectin-functionalized liposomes for pulmonary drug delivery: effect of nebulization on stability and bioadhesion. European Journal of Pharmaceutical Sciences, 2001, 14, 37-46.	1.9	84
367	Oral endotracheal intubation of rats for intratracheal instillation and aerosol drug delivery. Laboratory Animals, 2001, 35, 257-260.	0.5	24
368	Development of a new aerosol delivery system for systemic pulmonary delivery in anaesthetized and orotracheal intubated rats. Laboratory Animals, 2001, 35, 261-270.	0.5	5
369	Charge-dependent interaction of self-emulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity. International Journal of Pharmaceutics, 2000, 211, 29-36.	2.6	62
370	Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. International Journal of Pharmaceutics, 2000, 196, 177-182.	2.6	144
371	Visualization and quantification of polymer distribution in microcapsules by confocal laser scanning microscopy (CLSM). International Journal of Pharmaceutics, 2000, 196, 223-226.	2.6	38
372	Silica nanoparticles modified with aminosilanes as carriers for plasmid DNA. International Journal of Pharmaceutics, 2000, 196, 257-261.	2.6	261
373	Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rats. European Journal of Pharmaceutical Sciences, 2000, 9, 253-258.	1.9	20
374	Biodegradable microparticles as a two-drug controlled release formulation: a potential treatment of inflammatory bowel disease. Journal of Controlled Release, 2000, 69, 445-454.	4.8	64
375	Lectin-mediated drug delivery:. Journal of Controlled Release, 2000, 65, 19-29.	4.8	268
376	Drug distribution in human skin using two different in vitro test systems: comparison with in vivo data. Pharmaceutical Research, 2000, 17, 1475-1481.	1.7	111
377	Structural analysis of microparticles by confocal laser scanning microscopy. AAPS PharmSciTech, 2000, 1, 10-19.	1.5	53
378	Characterization of microcapsules by confocal laser scanning microscopy: structure, capsule wall composition and encapsulation rate. European Journal of Pharmaceutics and Biopharmaceutics, 2000, 49, 1-9.	2.0	116

#	Article	IF	Citations
379	A Nonviral DNA Delivery System Based on Surface Modified Silica-Nanoparticles Can Efficiently Transfect Cells in Vitro. Bioconjugate Chemistry, 2000, 11, 926-932.	1.8	319
380	Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification. International Journal of Pharmaceutics, 1999, 184, 97-105.	2.6	147
381	Organic cation transport in rabbit alveolar epithelial cell monolayers. Pharmaceutical Research, 1999, 16, 1280-1287.	1.7	22
382	Monolayers of human alveolar epithelial cells in primary culture for pulmonary absorption and transport studies. Pharmaceutical Research, 1999, 16, 601-608.	1.7	151
383	Transport of proteolytic enzymes across Caco-2 cell monolayers. Pharmaceutical Research, 1998, 15, 1393-1400.	1.7	25
384	Lectins and bacterial invasion factors for controlling endo- and transcytosis of bioadhesive drug carrier systems. European Journal of Pharmaceutics and Biopharmaceutics, 1997, 44, 3-13.	2.0	52
385	Binding, Uptake, and Transport of Hypericin by Caco-2 Cell Monolayers. Journal of Pharmaceutical Sciences, 1997, 86, 1120-1126.	1.6	47
386	Mucoadhesive polymers in peroral peptide drug delivery. IV. Polycarbophil and chitosan are potent enhancers of peptide transport across intestinal mucosae in vitro. Journal of Controlled Release, 1997, 45, 15-23.	4.8	165
387	Simultaneous in vivo visualization and localization of solid oral dosage forms in the rat gastrointestinal tract by magnetic resonance imaging (MRI). Pharmaceutical Research, 1997, 14, 1066-1072.	1.7	31
388	Mucoadhesive polymers in peroral peptide drug delivery. I. Influence of mucoadhesive excipients on the proteolytic activity of intestinal enzymes. European Journal of Pharmaceutical Sciences, 1996, 4, 117-128.	1.9	96
389	The potential of mucoadhesive polymers in enhancing intestinal peptide drug absorption. III: Effects of chitosan-glutamate and carbomer on epithelial tight junctions in vitro. Journal of Controlled Release, 1996, 39, 131-138.	4.8	369
390	Mucoadhesive properties of the mussel adhesive protein. International Journal of Pharmaceutics, 1996, 141, 251-256.	2.6	58
391	From sticky stuff to sweet receptors — achievements, limits and novel approaches to bioadhesion. European Journal of Drug Metabolism and Pharmacokinetics, 1996, 21, 139-148.	0.6	86
392	Mucoadhesive polymers in peroral peptide drug delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharmaceutical Research, 1995, 12, 1293-1298.	1.7	146
393	Bioadhesive polymers for the peroral delivery of peptide drugs. Journal of Controlled Release, 1994, 29, 329-338.	4.8	140
394	Binding and transport of some bioadhesive plant lectins across Caco-2 cell monolayers. Pharmaceutical Research, 1993, 10, 1796-1799.	1.7	35
395	A surface energy analysis of mucoadhesion II. Prediction of mucoadhesive performance by spreading coefficients. European Journal of Pharmaceutical Sciences, 1993, 1, 19-30.	1.9	59
396	Visualization studies of the mucoadhesive interface. Journal of Controlled Release, 1992, 18, 249-260.	4.8	27

#	Article	IF	CITATIONS
397	Bioadhesion by means of specific binding of tomato lectin. Pharmaceutical Research, 1992, 09, 547-553.	1.7	108
398	A surface energy analysis of mucoadhesion: contact angle measurements on polycarbophil and pig intestinal mucosa in physiologically relevant fluids. Pharmaceutical Research, 1992, 09, 70-75.	1.7	102
399	Niosomes for oral delivery of peptide drugs. Journal of Controlled Release, 1992, 21, 145-153.	4.8	64
400	In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. International Journal of Pharmaceutics, 1992, 78, 43-48.	2.6	895
401	An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop. International Journal of Pharmaceutics, 1991, 70, 235-240.	2.6	189
402	Intestinal transit of bioadhesive microspheres in an in situ loop in the ratâ€"A comparative study with copolymers and blends based on poly(acrylic acid). Journal of Controlled Release, 1990, 13, 51-62.	4.8	170
403	A New Immortalized Human Alveolar Epithelial Cell Model to Study Lung Injury and Toxicity on a Breathing Lung-On-Chip System. Frontiers in Toxicology, 0, 4, .	1.6	17